ArticleFrontiers in endocrinology2026
Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Semaglutide has shown significant efficacy in several clinical trials for the treatment of obesity. However, real-world data on early weight loss and metabolic response in obesity without diabetes cohort are still limited, particularly with respect to individual patient factors. This study aims to evaluate the real-world effectiveness of semaglutide on anthropometric and metabolic parameters in an obesity cohort, including weight loss (kg and percent) and the percentage of participants achieving the 5%, 10% and 15% weight loss targets at mean 3-month, 6-month and 12-month follow-up. In addition, an assessment of safety and reasons for discontinuation, and sub-analyses of anthropometric outcomes by prior liraglutide exposure, sex, and BMI categories will be included. Methods: In this retrospective study, data were collected from adults with overweight/obesity without diabetes treated with weekly subcutaneous semaglutide for at least 3 months and analyzed at 2-4 (T1), 5-8 (T2), and 9-15 (T3) months of follow-up. Results: Among 248 patients (55.0 years, 34.8 kg/m Conclusions: These results confirm semaglutide's effectiveness on cardiometabolic risk in real-world obesity management, with a safety profile and early metabolic effects independent of weight loss. The reduced early response in switchers and at low doses highlights the importance of dose optimization to prevent suboptimal initial outcomes after switching. The lack of differences by sex and BMI category supports further studies stratifying patients by age and metabolic risk rather than BMI alone. Low persistence highlights the need for structured, patient-centered support to improve adherence and a better understanding of the drivers of discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.